EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia

Julia Laporte-Amargos iD, Marta Ulldemolins iD, María Patricia Hernández-Mitre iD, Jason A Roberts, Raul Rigo-Bonnin, Francisco Carmona-Torre, Maria Huguet, Pedro Puerta-Alcalde, Montserrat Arnan, Jose Luis Del Pozo, Anna Torrent, Carolina García-Vidal iD und 5 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01253-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Julia Laporte-Amargos und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Febrile Neutropenia, Piperacillin, Penicillanic Acid. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Primary Health Care Research Institute, Australian National University, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure. We aimed to characterize the population pharmacokinetics of piperacillin in plasma and provide optimized dosing recommendations for this patient population. A population pharmacokinetic analysis was conducted in patients who received piperacillin-tazobactam as part of the BEATLE study, which compared the efficacy, safety, and pharmacokinetic/pharmacodynamic target attainment of β-lactams administered in extended infusion versus short 30 min infusion in adult hematological patients with febrile neutropenia. Monte Carlo simulations were performed to evaluate, for each dosing regimen, the probability of attaining (i) an efficacy target of unbound piperacillin concentrations above the minimum inhibitory concentration (MIC) of the bacteria for the entire dosing interval (100% ƒ T >MIC ), and (ii) a toxicity threshold of ≥160 mg/L. A total of 44 patients and 221 plasma concentrations were included. A one-compartment model best described piperacillin plasma pharmacokinetics, with Cockcroft-Gault creatinine clearance (CrCL) significantly influencing drug clearance. Dosing simulations showed that extended and continuous infusions were superior to short 30 min infusions in the attainment of 100% ƒ T >MIC , even for bacteria with low to intermediate MIC (≤2–4 mg/L). In patients with higher CrCL (>90 mL/min) or infections caused by less susceptible Gram-negative bacilli (MIC: 8–16 mg/L), only continuous infusions of 12–16 g/day were likely to achieve 100% ƒ T >MIC . These findings support the use of extended or continuous infusions of piperacillin in the initial management of patients with febrile neutropenia, particularly in patients with higher CrCL or when infections caused by less susceptible pathogens, such as Pseudomonas aeruginosa , are suspected.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsFebrile NeutropeniaPiperacillinPenicillanic AcidHumansPiperacillin, Tazobactam Drug CombinationFemaleMiddle AgedMaleMicrobial Sensitivity TestsAdultAgedMonte Carlo MethodInfusions, Intravenous

Stichwörter der Autor:innen

continuous infusioncreatinine clearanceextended infusionfebrile neutropeniapharmacokineticspharmacokinetics/pharmacodynamicspiperacillin-tazobactam

Substanzen

Piperacillin, Tazobactam Drug CombinationAnti-Bacterial AgentsPiperacillinPenicillanic Acid

Autor:innen und Institutionen

  • Department of Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
  • School of Medicine, University of Barcelona, Barcelona, Spain.
  • UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences (HMBS), The University of Queensland, Brisbane, Queensland, Australia.
  • Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Australia.
  • Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane, Australia.
  • Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.

ORCID-Profile: Julia Laporte-Amargos, Marta Ulldemolins, María Patricia Hernández-Mitre, Carolina García-Vidal

Förderung

  • Australian Primary Health Care Research Institute, Australian National University
  • Instituto de Salud Carlos III

Zitieren

APA

Laporte-Amargos, J., Ulldemolins, M., Hernández-Mitre, M. P., Roberts, J. A., Rigo-Bonnin, R., Carmona-Torre, F., Huguet, M., Puerta-Alcalde, P., Arnan, M., Del Pozo, J. L., Torrent, A., García-Vidal, C., Sureda, A., Bergas, A., Sastre-Escolà, E., Carratalà, J., & Gudiol, C. (2026). Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01253-25

Vancouver

Laporte-Amargos J, Ulldemolins M, Hernández-Mitre MP, Roberts JA, Rigo-Bonnin R, Carmona-Torre F, et al. Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01253-25

BibTeX
@article{LaporteAmargos2026,
  author = {Laporte-Amargos, Julia and Ulldemolins, Marta and Hernández-Mitre, María Patricia and Roberts, Jason A and Rigo-Bonnin, Raul and Carmona-Torre, Francisco and Huguet, Maria and Puerta-Alcalde, Pedro and Arnan, Montserrat and Del Pozo, Jose Luis and Torrent, Anna and García-Vidal, Carolina and Sureda, Anna and Bergas, Alba and Sastre-Escolà, Enric and Carratalà, Jordi and Gudiol, Carlota},
  title = {Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01253-25}
}
Kostenlos starten →